Is patient travel distance associated with survival on phase II clinical trials in oncology?

Journal of the National Cancer Institute

Volumn 95, Issue 18, 2003, Pages 1370-1375

  Lamont, Elizabeth B ^a,d   Hayreh, Davinder ^b   Pickett, Kate E ^a   Dignam, James J ^a   List, Marcy A ^a   Stenson, Kerstin M ^a   Haraf, Daniel J ^a   Brockstein, Bruce E ^c   Sellergren, Sarah A ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; HYDROXYUREA; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL STUDY; CONTROLLED STUDY; DEMOGRAPHY; ECONOMIC ASPECT; FEMALE; GEOGRAPHY; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TRAVEL; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RISK; STATISTICS; SURVIVAL RATE; UNITED STATES; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; BIAS (EPIDEMIOLOGY); CANCER CARE FACILITIES; CARCINOMA, SQUAMOUS CELL; CHICAGO; CLINICAL TRIALS, PHASE II; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HOSPITALS, UNIVERSITY; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERRAL AND CONSULTATION; SURVIVAL RATE; TRAVEL;

EID: 0141617568     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg035     Document Type: Article

References (37)

1. Lenhard RE, Enterline JP, Crowley J, Ho GY. The effects of distance from primary treatment centers on survival among patients with multiple myeloma. J Clin Oncol 1987;5:1640-5.
2. Warner MA, Hosking MP, Lobdell CM, Melton U. Effects of referral bias on surgical outcomes: a population-based study of surgical patients 90 years of age or older. Mayo Clin Proc 1990;65:1185-91.
3. Ballard DJ, Bryant SC, O'Brien PC, Smith DW, Pine MB, Cortese DA. Referral selection bias in the Medicare hospital mortality prediction model: are centers of referral for Medicare beneficiaries necessarily centers of excellence? Health Serv Res 1994;28:771-84.
4. Goodman DC, Fisher E, Stukel TA, Chang C. The distance to community medical care and the likelihood of hospitalization: is closer always better? Am J Public Health 1997;87:1144-50.
5. Paltiel O, Ronen I, Polliack A, Epstein L. Two-way referral bias: evidence from a clinical audit of lymphoma in a teaching hospital. J Clin Epidemiol 1998;51:93-8.
6. Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Humerickhouse R, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-61.
7. Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-9.
8. Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689-97.
9. Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21:320-6.
10. Brockstein BE, Haraf DJ, Kies MS, Stenson K, Mittal B, Pelzer H. Survival, patterns of failure, and risk factors for recurrence after intensive concomitant chemoradiation (CRT) for squamous cell head and neck cancer [abstract]. Proc ASCO 2002;21:918.
11. American Joint Commission on Cancer. Handbook for staging of cancer. Philadelphia (PA): Lippincott-Raven; 1992.
12. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1:634-56.
13. Bassett MT, Krieger N. Social class and black-white differences in breast cancer survival. Am J Public Health 1986;76:1400-3.
14. Walker AP, Neal L, Ausman RK, Whipple J, Doherty B. Per capita income in breast cancer patients. J Natl Med Assoc 1989;81:1065-8.
15. Boyd C, Zhang-Salomons JY, Groome PA, Mackillop, WJ, et al. Associations between community income and cancer survival in Ontario, Canada, and the United States. J Clin Oncol 1999:17:2244-55.
16. Charlson ME, Pompei P, Alex KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
17. Robinson JC, Luft HS, McPhee SJ, Hunt SS. Hospital competition and surgical length of stay. JAMA 1988;259:696-700.
18. Welch HG, Larson EB, Welch WP. Could distance be a proxy for severity-of-illness? A comparison of hospital costs in distant and local patients. Health Serv Res 1993;28:441-58.
19. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
20. Grambsch PM, Therneau TM. Proportional hazards test and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
21. Kawachi I, Berkman L. Social cohesion, social capital, and health. In: Berkman LF, Kawachi I, editors. Social epidemiology. New York (NY): Oxford University Press; 2000. p. 174-90.
22. Brizel DM, Leopold KA, Fisher SR, Panella TJ, Fine RL, Bedrosian CL, et al. A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1994;28:213-20.
23. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338: 1798-1804.
24. Adelstein DJ, Adams GL, Li Y, Wagner H, Kish J, Ensley J, et al. A phase III comparison of standard radiation therapy (Rt) versus Rt plus concurrent cisplatin (Ddp) versus split-course Rt plus concurrent Ddp and 5-fluorouracil in patients with unresectable, squamous cell head and neck cancer [abstract]. Proc ASCO 2000;19:1624.
25. Al-Sarraf M, Pajak TF, Marcial VA, Mowry P, Cooper JS, Stetz J, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. Cancer 1987;59:259-65.
26. Adelstein DJ, Kalish LA, Adams GL, Wagner H Jr, Oken MM, Remick SC, et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1993;11:2136-42.
27. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
28. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
29. Kunz R, Khan KS, Neumayer HH. Observational studies and randomized trials. N Engl J Med 2000;343:1194-5.
30. Fazzari M, Heller G, Scher HI. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials. Control Clin Trials 2000;21:360-8.
31. Tobacco smoking. IARC Monogr Eval Carcinog Risk Chem Hum 1986; 38:35-394.
32. Lantz PM, House JS, Lepkowski JM, Williams DR, Mero RP, Chen J. Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. JAMA 1998;279: 1703-8.
33. Polednak AP. Survival of breast cancer patients in Connecticut in relation to socioeconomic and health care access indicators. J Urban Health 2002; 79:211-8.
34. Stavraky KM, Skillings JR, Stitt LW, Gwadry-Sridhar F. The effect of socioeconomic status on the long-term outcome of cancer. J Clin Epidemiol 1996;49:1155-60.
35. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US white and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002;162: 1985-93.
36. Lee AJ, Baker CS, Gehlbach S, Hosmer DW, Reti M. Do black elderly Medicare patients receive fewer services? An analysis of procedure use for selected patient conditions. Med Care Res Rev 1998:55:314-33.
37. Lee K, Strauss M. Head and neck cancer in blacks. J Natl Med Assoc 1994;86:530-4.